Version 2.76

Term Description

Quantitative result for Zika virus neutralizing antibodies in a convalescent phase CSF sample. Serological cross-reactivity is strong between Zika and other flaviviruses, especially Dengue virus. Therefore, positive EIA or IF assays for Zika virus IgM antibodies are presumptive only and should be confirmed by a neutralization assay, such as the plaque-reduction neutralization test (PRNT), which can discriminate between Zika virus and cross-reacting antibodies in primary flavivirus infections. Recent Zika virus infection is confirmed by stable high neutralizing antibody titers, seroconversion, or a 4x or greater increases in neutralizing antibody titer in a patient's appropriately timed acute and convalescent phase specimens.
Source: Regenstrief LOINC

Part Descriptions

LP200137-0   Zika virus
Zika virus (ZIKV) is a flavivirus transmitted primarily by the Aedes mosquito which was first identified in a sentinel monkey in the Zika forest in Uganda in 1947. Since 2014 it has spread explosively in the Americas where it has infected hundreds of thousands of people. About 80% of those infected are asymptomatic. Common symptoms include fever, headache, rash, arthralgia and conjunctivitis. Since the end of 2015, there has been an increase in ZIKV-associated cases of Guillain-Barre syndrome and a tremendous increase in cases of microcephaly in fetuses and newborns in Brazil, raising worldwide public health concern. Recent predictions are that the mosquito species A. Albopictus, which can hibernate and survive cool temperatures, will carry ZIKV to more temperate areas of North America, Australia and Southern Europe. It is still not clear whether ZIKV in humans increases viral titers enough to trigger a new cycle when an infected person is bitten by a naïve mosquito. Direct human-to-human transmission has been documented to occur perinatally, sexually (primarily through semen), through breastfeeding, blood transfusion and through occupational transmission in the laboratory setting. There are currently no specific anti-viral agents, vaccination or medical prophylaxis available. PMID: 27148186 Source: Regenstrief LOINC

LP207365-0   Ab.Neut
Neutralizing antibodies are antibodies that interfere with the interaction between the virus and its host cell receptor, therefore preventing infectivity. Neutralizing antibodies can be detected using a traditional VNT or other methods such as pseudovirus VNT and surrogate VNT. VNT and pseudovirus VNT use live virus (the actual virus or a recombinant virus that incorporates the viral antigen of interest, respectively) and cell culture to assess the virus-host interaction and whether neutralizing antibodies are present that block that interaction. Surrogate VNT (sVNT) does not use live virus but rather uses purified viral antigen and host cell receptor protein to mimic the same interaction. The sVNT method is currently (2021) represented in LOINC as IA, because it is an immunoassay-based method. Source: Regenstrief LOINC

LP6416-4   Neut
In LOINC, the Method "Neut" represents the virus neutralization test (VNT), also called conventional VNT, which is a specific laboratory method that is used primarily for identifying whether neutralizing antibodies for the virus of interest are present in the patient sample. The VNT involves incubating patient serum with the virus of interest, and then inoculating onto cell culture. If neutralizing antibodies are present and the virus is neutralized, the cells will not be infected. If neutralizing antibodies are not present, the virus will infect the cells in the cell culture. PMID: 32170698 This method can also be used to identify specific virus serotypes or strains, by performing separate tests in which serum is incubated with each of the specific virus serotypes or strains of interest. PMID: 169804 Source: Regenstrief LOINC

Fully-Specified Name

Component
Zika virus Ab.Neut^2nd specimen
Property
Titr
Time
Pt
System
CSF
Scale
SemiQn
Method
Neut

Additional Names

Short Name
ZIKV NAb sp2 Titr CSF Nt
Display Name
ZIKV neut ab spec 2 Neut test (CSF) [Titer]
Consumer Name Alpha Get Info
Zika virus neutralizing antibody specimen 2, Spinal fluid

Basic Attributes

Class
MICRO
Type
Laboratory
First Released
Version 2.56
Last Updated
Version 2.75
Order vs. Observation
Both

Member of these Groups Get Info

LOINC Group Group Name
LG32774-8 Zika virus

Language Variants Get Info

Tag Language Translation
es-ES Spanish (Spain) Virus Zika Anticuerpos antineutrófilos^2º especimen:Titulo / Factor de dilución:Punto temporal:Líquido Cefalorraquideo:Semicuantitativo:Prueba de neutralización
Synonyms: Semicuantitativo
es-MX Spanish (Mexico) Ab.Neut del virus del Zika ^2da muestra:Título:Punto temporal:Fluído espinal cerebral:Cuantitativo:Prueba de neutralización
fr-FR French (France) Zika virus Ac neutralisant 2nd prélèvement:Titre:Ponctuel:Liquide céphalorachidien:Semi-Quantitatif:Neutralisation
it-IT Italian (Italy) Zika virus Ab.Neut^2° campione:Titr:Pt:LCS:SemiQn:Neut
Synonyms: anticorpo Liquido cerebrospinale Microbiologia Punto nel tempo (episodio) Test di neutralizzazione Titolo Virus Zika
nl-NL Dutch (Netherlands) zikavirus As.neutraliserend^2de monster:titer:moment:liquor cerebrospinalis:semikwantitatief:neutralisatietest
Synonyms: antistof; antilichaam Zika-virus
zh-CN Chinese (China) 寨卡病毒 抗体.中和^第2个标本:滴定度:时间点:脑脊液:半定量型:中和试验
Synonyms: Ab;自身抗体 CSF CSF;脊髓液;Cerebral spinal fluid;脑脊髓液 中和试验;中和抗体;中和 传染毒;传染毒素;滤过性病原体;病毒类;过滤性病原体 免疫之后 免疫之后的标本 免疫后 免疫后标本 受检物 在免疫之后 塞卡病毒;Zika virus;Zika 病毒;ZIKV;济卡病毒;兹卡病毒 康复期 康复期标本 微生物学;微生物学试验;微生物学试验(培养、DNA、抗原及抗体) 恢复期 恢复期标本 效价;滴定浓度;滴定率;滴定量;滴度;稀释倍数;稀释因子;稀释系数 时刻;随机;随意;瞬间 样品 样本 第2 第2个标本(样本、样品、试样) 第二 第二个 第二个标本 脊液 脊髓液 脑脊液(Cerebral spinal fluid,CSF) 脑脊髓液 试样

Example Units

Unit Source
{titer} Example UCUM Units

LOINC Terminology Service (API) using HL7® FHIR® Get Info

CodeSystem lookup
https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=80625-7